A5070193149- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Eosinophilic Disorders and Syndromes
- Polyomavirus and related diseases
- Renal Transplantation Outcomes and Treatments
- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Neutropenia and Cancer Infections
- T-cell and B-cell Immunology
- Hemoglobinopathies and Related Disorders
- SARS-CoV-2 and COVID-19 Research
- Kruppel-like factors research
- COVID-19 Clinical Research Studies
- Histone Deacetylase Inhibitors Research
- Childhood Cancer Survivors' Quality of Life
- Mesenchymal stem cell research
- COVID-19 and healthcare impacts
- Immunotherapy and Immune Responses
- Immunodeficiency and Autoimmune Disorders
City of Hope
2016-2025
City Of Hope National Medical Center
2016-2025
Beckman Research Institute
2019-2025
Lady Reading Hospital
2025
Abbott (United States)
2024
Cogent Biosciences (United States)
2024
Bristol-Myers Squibb (Germany)
2024
AbbVie (United States)
2024
Blueprint Medicines (United States)
2024
Merck Institute for Science Education
2024
The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN) consist of myelofibrosis, polycythemia vera, and essential thrombocythemia are a heterogeneous group clonal blood disorders characterized by an overproduction cells. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for MPN were developed as result meetings convened multidisciplinary panel with expertise MPN, the goal providing recommendations management adults. include diagnostic workup, risk...
Abstract Acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic cell transplantation (HCT) is a primary cause of nonrelapse mortality and major barrier to successful transplant outcomes. Itacitinib Janus kinase (JAK)1–selective inhibitor that has demonstrated efficacy in preclinical models aGVHD. We report results from the first registered study JAK patients with This was an open-label phase 1 enrolling aged ≥18 years HCT any source who developed grade IIB IVD Patients...
Abstract Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF patients treated with allogeneic HCT (551 patients) and without (non-HCT) (1377 was analyzed Cox proportional hazards model. Survival analysis stratified by Dynamic International Prognostic Scoring System (DIPSS) revealed that first year of treatment arm assignment, due to upfront risk transplant-related...
The safety and efficacy of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) emergency-use authorized (EUA) vaccines have been confirmed in general population. However, there are no data on its tolerability or recipients allogeneic hematopoietic stem cell transplant (HCT). We performed this study to identify incidence adverse events following SARS-CoV2 EUA vaccines, new-onset graft-versus-host disease (GVHD) worsening existing GVHD after vaccine administration, positivity...
We reported that an acquired miR-142 deficit transforms chronic phase (CP) myeloid leukemia (CML) leukemic stem cells (LSCs) into blast crisis (BC) LSCs. Given the role of in development and activity immune system, we postulated this also promotes LSC escape. Herein, report on IL-6-driven occurring T during BC transformation. In CML murine models, impairs thymic differentiation lymphoid-primed multipotent progenitors (LMPP) prevents cells' metabolic reprogramming, thereby leading to loss...
PURPOSE This phase I-Ib trial evaluated a novel CD40L blocking antibody, BMS-986004, for the prevention of graft-versus-host disease (GVHD) after unrelated donor allogeneic hematopoietic cell transplantation (HCT). PATIENTS AND METHODS A total 34 patients were treated at three centers. The safety and biologic activity single-dose BMS-986004 (675 mg [n = 6] 1,500 6]; one-time dose) evaluated. Safety prolonged dosing was then examined in separate cohorts (drug administration every 2 weeks × 3...
Current conditioning regimens provide insufficient disease control in relapsed/refractory acute leukemia patients undergoing hematopoietic stem cell transplantation (HSCT) with active disease. Intensification of chemotherapy and/or total body irradiation (TBI) is not feasible because excessive toxicity. Total marrow and lymphoid (TMLI) allows for precise delivery increased intensity treatment via sculpting radiation to sites high burden or risk involvement, while sparing normal tissue. We...
Chronic graft-versus-host disease (cGVHD) continues to be a major complication after allogeneic hematopoietic cell transplantation, significantly affecting patients' quality of life. A regimen systemic corticosteroids is considered first-line therapy but often associated with inadequate responses and multiple side effects. In patients refractory disease, an evidenced-based consensus lacking as the single best approach managing symptoms. Ruxolitinib, selective JAK1/2 inhibitor, has recently...
The combination of venetoclax with hypomethylating agents (VEN-HMAs) showed promising activity in newly diagnosed and relapsed/refractory (r/r) acute myeloid leukemia (AML). Treatment VEN-HMAs results prolonged cytopenia, thereby exposing patients to invasive fungal infections (IFIs). Here, we retrospectively studied a cohort 119 AML treated analyzed the occurrence IFIs, as well our practice antifungal prophylaxis, aim identify nature risk factors for IFIs their association type prophylaxis...
Abstract Although allogeneic hematopoietic cell transplantation (allo-HCT) is the only curative treatment for myelofibrosis (MF), data are limited on how molecular markers predict outcomes. We retrospectively evaluated outcomes of 110 consecutive MF patients who underwent allo-HCT with a fludarabine/melphalan (Flu/Mel) conditioning regimen at our center and assessed impact based 72-gene next-generation sequencing panel Mutation-Enhanced International Prognostic Scoring System 70+ v2.0...
Efficacy of PTCy after mismatched unrelated donor (MMUD) HCT is unknown. In this pilot clinical trial, we enrolled 38 patients with hematologic malignancies scheduled to undergo MMUD-HCT (≥6/8 HLA-matched donors) onto 1 2 conditioning strata: myeloablative using fludarabine and fractionated total body irradiation (n = 19) or reduced intensity fludarabine/melphalan 19). Graft source was peripheral blood stem cells (PBSCs), GVHD prophylaxis PTCy, tacrolimus, mycophenolate mofetil. Patients'...
Abstract Ruxolitinib reduces spleen volume, improves symptoms, and increases survival in patients with intermediate- or high-risk myelofibrosis. However, suboptimal response may occur, potentially because of signaling via the phosphoinositide 3-kinase (PI3K)/protein kinase B pathway. This phase 2 study evaluated dosing, efficacy, safety add-on PI3Kδ inhibitor parsaclisib for primary secondary myelofibrosis to ruxolitinib. Eligible remained on a stable ruxolitinib dose received 10 20 mg, once...
The tyrosine kinase inhibitor dasatinib is often used after allogeneic hematopoietic cell transplantation to treat minimal residual disease in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Colitis, sometimes hemorrhagic, has occasionally been described with the use of for both chronic myeloid and Ph+ ALL. pathogenesis dasatinib-induced colitis unclear but may be related effects on immune function. We describe a series 5 patients who had 7 episodes during use. No...
Therapy-related acute lymphoblastic leukemia remains poorly defined due to a lack of large data sets recognizing the defining characteristics this entity. We reviewed all consecutive cases adult treated at our institution between 2000 and 2017 identified therapy-related - as preceded by prior exposure cytotoxic chemotherapy and/or radiation. Of 1022 patients with leukemia, 93 (9.1%) were classified therapy-related. The median latency for onset was 6.8 years from original diagnosis, shorter...
The combination of hypomethylating agents with the selective Bcl-2 inhibitor venetoclax (HMA-VEN) has emerged as a highly active regimen in patients acute myelogenous leukemia (AML) both upfront and relapsed/refractory (r/r) settings. We report our early experience cohort who were able to proceed allogeneic hematopoietic cell transplantation (alloHCT) after HMA-VEN therapy. Thirty-two AML (19 r/r 13 de novo) median age 62 years underwent alloHCT Twenty-two (68.8%) complete remission (CR)/CR...
Background Blinatumomab has demonstrated encouraging activity in relapsed/refractory (r/r) and minimal residual disease–positive (MRD+) acute lymphoblastic leukemia (ALL). Extramedullary disease (EMD) relapse or with CD19– been observed after blinatumomab therapy patients r/r MRD+ ALL. However, the pathophysiology risk factors of treatment failure are not fully understood. Methods This study retrospectively reviewed outcomes adult B‐cell ALL treated (n = 132) for either 103) 29) at authors'...
We report results of our prospective pilot trial evaluating safety/feasibility peritransplantation ruxolitinib for myelofibrosis treatment. Primary objectives were to determine safety and maximum tolerated dose (MTD) ruxolitinib. Ruxolitinib was administered at 2 levels (DLs) 5 10 mg twice daily, with fludarabine/melphalan conditioning regimen tacrolimus/sirolimus graft-versus-host disease (GVHD) prophylaxis. enrolled 6 12 patients DL1 DL2, respectively. Median age transplantation 65 years...
Allogenic hematopoietic cell transplantation (alloHCT) is a well-established curative modality for acute lymphoblastic leukemia (ALL), yet large amounts of data describing alloHCT outcomes in Philadelphia (Ph)-like ALL are lacking. We retrospectively analyzed archived DNA samples from consecutive adults with B-cell Ph-negative who underwent complete remission (CR) (n = 127) at our center between 2006 and 2020. Identification fusions associated Ph-like was performed using cumulative results...
Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL) is associated with a poor response to standard chemotherapy. However, outcomes novel antibody and cellular therapies in relapsed/refractory (r/r) Ph-like ALL are largely unknown. We conducted single-center retrospective analysis of adult patients (n = 96) r/r B-ALL fusions who received salvage therapies. Patients were treated 149 individual regimens (blinatumomab 83, inotuzumab ozogamicin [InO] 36, CD19CAR T cells 30). The median age...